Related Experiment Video
Updated: Sep 23, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab
Daniel Mazzoni1, Yolanka Lobo1, David Levitt2
1Department of Dermatology, Queensland Children's Hospital, Brisbane, Queensland, Australia.
Insights
Dupilumab offers a new targeted treatment for severe atopic dermatitis (AD). This case study shows its successful use in a 21-month-old child with severe, difficult-to-treat AD.
Area of Science:
- Dermatology
- Pediatric Allergy and Immunology
- Pharmacology
Background:
- Severe atopic dermatitis (AD) poses significant challenges in young children.
- Limited data exists on the efficacy and safety of novel systemic treatments like dupilumab in this age group.
- Recalcitrant AD in infants requires effective and safe therapeutic options.
Abstract:
While dupilumab has emerged as a novel targeted systemic treatment for severe AD, efficacy and safety-based data in young children are limited. We discuss the case of a 21-month-old child with severe recalcitrant atopic dermatitis successfully treated with dupilumab.
Related Concept Videos
Allergic Drug Reactions
Allergic Reactions

